Pancreatic ductal adenocarcinoma (PDAC) is known for its resistance to gemcitabine, which
acts to inhibit cell growth by termination of DNA replication. Tumor-associated macrophages …

Simple Summary Previous studies have shown that cancer associated fibroblasts exposed
to chemotherapy release exosomes which promote chemoresistance in recipient cells …

The cancer drug gemcitabine (GEM) is a key drug for treating pancreatic ductal
adenocarcinoma (PDAC), but PDAC cells develop chemoresistance after long-term …

Purpose Macrophages are a major component of the tumour microenvironment and play an
important role in chemoresistance of cancer. However, how exosomal microRNAs (miRNAs) …

Purpose Gemcitabine (GEM)-based chemotherapy is the first-line treatment for locally
advanced pancreatic cancer. GEM resistance, however, remains a significant clinical …

Background: Chemoresistance is a significant clinical problem in pancreatic cancer (PC)
and underlying molecular mechanisms still remain to be completely understood. Here we …

Background Although gemcitabine-based chemotherapy has been established as a core
multimodal therapy for non-small cell lung cancer (NSCLC) treatment, its clinical efficacy …

While adriamycin (adr) offers improvement in survival for breast cancer (BCa) patients,
unfortunately, drug resistance is almost inevitable. Mounting evidence suggests that …

Breast cancer (BCa) remains chemo-unresponsive by inevitable progression of resistance to
first-line treatment with docetaxel (doc). Emerging studies indicate that exosomes act as …

Gemcitabine (GEM)-based chemotherapy is commonly used to treat pancreatic cancer.
However, acquired resistance to GEM remains a challenge in pancreatic cancer patients …